UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 143

Sortiert nach

Oncolytic virus-derived type I interferon restricts CAR T cell therapy

Nature communications, 2020-06, Vol.11 (1), p.3187-3187, Article 3187

2020

Volltextzugriff (PDF)

Immune characterization of metastatic colorectal cancer patients post reovirus administration

BMC cancer, 2020-06, Vol.20 (1), p.569-11, Article 569

2020

Volltextzugriff (PDF)

Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults

Molecular therapy, 2014-05, Vol.22 (5), p.1056-1062

2014

Volltextzugriff (PDF)

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

Investigational new drugs, 2013-06, Vol.31 (3), p.696-706

2013

Volltextzugriff (PDF)

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

Clinical cancer research, 2010-11, Vol.16 (22), p.5564-5572

2010

Volltextzugriff (PDF)

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

Clinical cancer research, 2008-11, Vol.14 (21), p.7127-7137

2008

Volltextzugriff (PDF)

Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma

Molecular therapy. Oncolytics, 2019-12, Vol.15, p.49-59

2019

Volltextzugriff (PDF)

Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence

Nature medicine, 2013-12, Vol.19 (12), p.1625-1631

2013

Volltextzugriff (PDF)

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

The Journal of immunology (1950), 2008-05, Vol.180 (9), p.6018-6026

2008

Volltextzugriff (PDF)

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

Science translational medicine, 2012-06, Vol.4 (138), p.138ra77

2012

Volltextzugriff (PDF)

Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

Clinical cancer research, 2008-01, Vol.14 (1), p.259-269

2008

Volltextzugriff (PDF)

Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses

Molecular therapy. Methods & clinical development, 2016-01, Vol.3 (C), p.16018-16018, Article 16018

2016

Volltextzugriff (PDF)

Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cells

International journal of cancer, 2013-05, Vol.132 (10), p.2327-2338

2013

Volltextzugriff (PDF)

Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma

Clinical cancer research, 2009-10, Vol.15 (19), p.6158-6166

2009

Volltextzugriff (PDF)

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming

Molecular cancer, 2011-02, Vol.10 (1), p.20-20, Article 20

2011

Volltextzugriff (PDF)

Oncolytic reovirus-mediated recruitment of early innate immune responses reverses immunotherapy resistance in prostate tumors

Molecular therapy. Oncolytics, 2021-03, Vol.20, p.434-446

2021

Volltextzugriff (PDF)

Oncolytic reovirus in canine mast cell tumor

PloS one, 2013-09, Vol.8 (9), p.e73555-e73555

2013

Volltextzugriff (PDF)

The oncolytic effects of reovirus in canine solid tumor cell lines

Journal of Veterinary Medical Science, 2015, Vol.77(5), pp.541-548

2015

Volltextzugriff (PDF)

Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic

Cancer research (Chicago, Ill.), 2010-03, Vol.70 (6), p.2435-2444

2010

Volltextzugriff (PDF)

582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A662-A662

2023

Volltextzugriff (PDF)

The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors

Methods (San Diego, Calif.), 2010-12, Vol.52 (4), p.301-306

2010

Volltextzugriff (PDF)

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e001803

2021

Volltextzugriff (PDF)

Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2

Clinical cancer research, 2009-01, Vol.15 (2), p.561-569

2009

Volltextzugriff (PDF)

Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

Clinical cancer research, 2008-02, Vol.14 (3), p.912-923

2008

Volltextzugriff (PDF)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

BMC cancer, 2012-08, Vol.12 (1), p.368-368, Article 368

2012

Volltextzugriff (PDF)

1 – 25 von 143

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(134)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(143)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Oncolytic virus-derived type I interferon restricts CAR T cell therapy

Immune characterization of metastatic colorectal cancer patients post reovirus administration

Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma

Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses

Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cells

Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming

Oncolytic reovirus-mediated recruitment of early innate immune responses reverses immunotherapy resistance in prostate tumors

Oncolytic reovirus in canine mast cell tumor

The oncolytic effects of reovirus in canine solid tumor cell lines

Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic

582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial

The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche

Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2

Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

Suchergebnisse filtern